RT Journal Article
T1 Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO.
A1 Llop, Maria
A1 Moreno, Mireia
A1 Navarro-Compán, Victoria
A1 Juanola, Xavier
A1 de Miguel, Eugenio
A1 Almodóvar, Raquel
A1 Quintana, Eduardo Cuende
A1 Sanz, Jesús Sanz
A1 Beltrán, Emma
A1 Montesinos, M Dolores Ruiz
A1 Calvet, Joan
A1 Berenguer-Llergo, Antoni
A1 Gratacós, Jordi
A1 Regisponserbio group, 
K1 Biological therapies
K1 Inflammation
K1 Outcome measures
K1 Radiology
K1 Spondyloarthritis
AB To evaluate the influence of the disease activity on radiographic progression in axial spondyloarthritis (axSpA) patients treated with TNF inhibitors (TNFi). The study included 101 axSpA patients from the Spanish Register of Biological Therapy in Spondyloarthritides (REGISPONSERBIO), which had clinical data and radiographic assessment available. Patients were classified into 2 groups based on the duration of TNFi treatment at baseline: (i) long-term treatment (≥4 years) and (ii) no long-term treatment ( Radiographic progression was defined as an increase in ≥2 mSASSS units. At inclusion, approximately half of the patients (45.5%) were receiving long-term treatment with TNFi (≥4 years). In this group of subjects, a significant difference in averaged Ankylosing Spondylitis disease Activity Score (ASDAS) across follow-up was found between progressors and non-progressors (2.33 vs 1.76, p=0.027, respectively). In patients not under long-term TNFi treatment (54.5%) though, no significant ASDAS differences were observed between progressors and non-progressors until the third year of follow-up. Furthermore, no significant differences were found in progression status, when disease activity was measured by Bath Ankylosing spondylitis Disease Activity Index (BASDAI) and C reactive protein (CRP). Patients on long-term TNFi treatment with a mean sustained low disease activity measures by ASDAS presented lower radiographic progression than those with active disease.
YR 2022
FD 2022-01-21
LK http://hdl.handle.net/10668/20357
UL http://hdl.handle.net/10668/20357
LA en
DS RISalud
RD Apr 6, 2025